Scan to Download iOS&Android APP

3M stock forecast: Will healthcare business spin-off unlock hidden value?

By  Yoke Wong

Edited by Vanessa Kintu


Share this article

What You Need to Know

The week ahead update on major market events in your inbox every week. Subscribe
3M logo on a building in Vilnius, Lithuania
3M’s Q2 results proved healthier than analysts had predicted – Photo: Karolis Kavolelis/

Shares in US-based industrial-consumer conglomerate 3M (MMM) have been on the rise, gaining 18.10% over the past month, as the group recently reported better-than-expected second-quarter earnings and announced that it would spin off its multi-billion-dollar healthcare business.

Formerly known as the Minnesota Mining and Manufacturing Company, the group makes diverse products across four business segments: safety and industrial, transportation and electronics, health care, and consumer. Some household 3M brands include Post-It, Scotch-Brite, Scotch, Scotchgard and Command.

Minnesota-headquartered 3M’s shares are listed on the New York Stock Exchange (NYSE) and closed at $152.24 on 12 August 2022. The stock has shown modest gains of 2.53% over the past month, but despite the recent growth remains down 14.29% from $177.74 at the beginning of the year.

Are you interested to learn more about the outlook for the group? Read this 3M stock analysis for the latest news and analysts’ 3M stock price forecasts before making your investment decision.

Q2 earnings report: Better than expected

On 26 July 2022, 3M reported adjusted earnings per share (EPS) of $2.48 in the second quarter, beating Wall Street’s forecast of $2.41, according to FactSet data quoted by Barron’s. Sales of $8.7bn were down year-over-year but still beat estimates of $8.57bn.

The company also reduced its full-year EPS projection to a range spanning from $10.30 to $10.80 – down from an earlier range of $10.75 to $11.25. Sales are also expected to come in between -0.5% and -2.5%, worse than management’s prior growth outlook of 1% to 4%.

The subdued projections were blamed on a stronger US dollar and the “uncertain macroeconomic environment”.

What is your sentiment on MMM?

Vote to see Traders sentiment!

Earplug business files for bankruptcy

According to a report by The New York Times, on 27 January 2022 the US District Court for the Northern District of Florida ordered 3M to pay $110m in damages to two US army veterans. 

The service members claimed they had hearing damage because the combat earplugs supplied by 3M were defective. Following the court judgement, there was a sell-off in 3M stocks, leading to a fall in the company’s share price.

3M’s stock price history showed that the group’s share prices were in downtrend for most of the second half of 2021 despite rising revenue last year. The falling 3M share price was partly driven by weaker market sentiment for the group, due to the ongoing lawsuits over its earplugs. 3M is still facing claims from over 290,000 former and current military members.

According to Reuters, “Out of the 16 trials to date involving 19 service members, plaintiffs have won in 10, with about $265m in combined awards to 13 plaintiffs.”

Aearo Technologies – the unit that manufactured the earplugs – has begun Chapter 11 proceedings in the Southern District of Indiana, 3M said on 26 July 2022.

The company has also committed $1bn to fund a trust aimed at resolving compensation-related claims, and will provide additional funding if required. 3M booked a pre-tax charge of $1.2bn in Q2 related to the expenses.

The bankruptcy manouevre has drawn criticism from the US military members suing the firm.

The action “is further proof that they value their profits and stock price more than the well-being of veterans who fought and served our country,” Bryan Aylstock, the court-appointed lead plaintiffs’ counsel in a lawsuit against 3M, said in a statement quoted by Bloomberg.

The market, however, reacted positively to the news, with shares climbing 5.7%.

“We view MMM's announcement to ring-fence its Combat Arms Earplugs litigation as a long-term positive (if contained to $1bn),” Citi Research analyst Andrew Kaplowitz said in a statement to Reuters.

3M to spin off healthcare business

On a separate note, 3M also announced that it would spin off its healthcare unit – responsible for close to 25% of the group’s $35.35bn in sales last year – into a separate public company.

The move means 3M will join a number of other manufacturers that intend to split their operations, simplify their businesses and boost investor returns. UK-based biotech giant GlaxoSmithKline (GSK) recently demerged from its consumer healthcare business, forming a new business called Haleon, which began trading on the London Stock Exchange (LSE) on Monday 18 July.

US industrial icon General Electric Co (GE) is also splitting its business into three separate parts. The multinational’s healthcare unit, GE Healthcare, will spin out of the broader company in 2023, followed by GE’s aviation and energy businesses in 2024, which will become GE Aerospace. Its power and renewables business will become GE Vernova (the name is a combination of ‘verde’ and ‘nova’, which mean ‘green’ in Spanish and ‘new’ in Latin, respectively).

According to a report from Bloomberg, “A spin-off could boost 3M’s sagging value, bolster its capital allocation strategy and give it a ‘liquidity war chest’.”

Bloomberg Intelligence analysts have suggested that the independent health business could be worth as much as $45bn.

However, some observers, including The Motley Fool's Lee Samaha, aren’t quite as optimistic regarding the move:

“The spin-off may well make sense, but it’s hard to argue that 3M’s healthcare business is being held back by the rest of 3M. In fact, it’s one of the problems, and despite concerted efforts over the years, its performance has been patchy at best. As such, 3M investors shouldn’t get too excited about the spin-off.
“A good comparison is made with GE Healthcare, a business GE is spinning off because it’s performing well and highly likely to unlock value. In contrast, 3M’s healthcare segment is actually one of its weak points that management has struggled to strengthen in recent years.”

3M will retain a stake of 19.9% in the new firm, which will focus on “wound care, oral care, healthcare IT, and biopharma filtration”. The conglomerate expects to complete the spin-off by the end of next year.


122.13 Price
-4.050% 1D Chg, %
Long position overnight fee -0.0064%
Short position overnight fee -0.0059%
Overnight fee time 21:00 (UTC)
Spread 0.15


269.43 Price
-6.230% 1D Chg, %
Long position overnight fee -0.0308%
Short position overnight fee -0.0137%
Overnight fee time 21:00 (UTC)
Spread 0.33


7.31 Price
-6.830% 1D Chg, %
Long position overnight fee -0.0308%
Short position overnight fee -0.0137%
Overnight fee time 21:00 (UTC)
Spread 0.22


142.43 Price
-4.750% 1D Chg, %
Long position overnight fee -0.0064%
Short position overnight fee -0.0059%
Overnight fee time 21:00 (UTC)
Spread 0.05

Food safety unit to merge with Neogen

Last week, 3M unveiled details of its $5.3bn scheme to spin off its food safety business, giving some upside to a stock that has trailed the broader market since the start of the year.

Shareholders will have the option to convert 3M shares, which trade on the NYSE, into stakes in the merger with Nasdaq-traded Neogen (NEOG). Following the transaction, Neogen is to be controlled by 3M.

A separate company, SpinCo, will be created to facilitate the conversion of 3M shares into Neogen shares.

3M’s 2022 outlook and drivers

According to investment guide website The Motley Fool, there are three potential positive factors that could support 3M’s stock value in 2022.

  • The recovery in the automotive sector could drive original equipment manufacturer (OEM) sales. 
  • Strong cash flow: “Adjusted free cash flow (FCF) generation of $6bn means the company has plenty of financial firepower to restructure and make acquisitions, even if you take out the $3.4bn in dividends paid,” Lee Samaha wrote on the website earlier this year.
  • Carryover benefits in 2022: “There would be $70m of carryover benefits from restructuring benefits that could be realised in 2022,” wrote Samaha, citing 3M’s chief financial officer Monish Patolawala.

In addition, the group has started to implement price increases to reflect higher raw material costs, starting with “a 0.1% year-over-year increase in the second quarter, leading to a 1.4% year-over-year increase in the third quarter and then a 2.6% year-over-year increase in the fourth quarter”.

Negative factors

The group is likely to face falling revenue from declining respirator sales in 2022 as Covid-19 infection rates subside, said Samaha.

In addition, 3M did not manage to “fully offset raw material cost increases to contribute to margin growth positively”.

The ongoing lawsuits regarding 3M’s Combat Arms earplugs sold to the US military will continue to weigh on investors’ sentiment.

Investor Reuben Gregg Brewer wrote on The Motley Fool on 21 July:

“Industrial giant 3M is working through tough times and is probably most appropriate for more aggressive investors. Notably, it has been trying to reinvigorate growth at the same time that it has been facing some material legal headwinds. The dividend yield is a historically high 4.5%, suggesting that the stock is cheap.”
“But there are a lot of positives here, including that the company has a huge $70bn market cap and an investment-grade balance sheet. It should be able to handle the legal headwinds it is facing today. As for getting growth back on track, 3M has a long history of innovation behind it. Technology breakthroughs are lumpy, but eventually, the company is likely to find another hit that it can put to good use throughout its portfolio.
“Meanwhile, the company’s least profitable division had an operating margin of 17.1% in the first quarter of 2022, providing a strong foundation to support the company as it works toward better days.”

Brewer believes that the company is a “timely buy amid the market sell-off”.

3M (MMM) stock price targets

MMM 5-year price chart

According to 3M stock predictions on MarketBeat, nine out of 14 Wall Street analysts surveyed had a ‘hold’ consensus rating for MMM stock while four maintained a ‘sell’ rating.

The average 12-month MMM stock price target was $152 with a 0.16% downside potential. In a positive scenario, analysts forecast the MMM share price could reach $205 while it could also fall to $118 in a negative scenario.

A number of banks updated their targets following 3M’s Q2 report, with Deutsche Bank slightly boosting its target from $146 to $148 on 27 July, which still indicated a potential upside of 5.15% on the report date.

Morgan Stanley's MMM stock forecast was bearish – the bank set a price target of $131 for the stock on 27 July, representing a potential downside of 5.83%. 

Wells Fargo upped its price target from $137 to $144 following 3M's earnings report while maintaining an ‘equal weight’ rating on the stock.

Credit Suisse posted the most optimistic projection, raising its target price to $160 from $157 — a potential upside of 15.02%.

3M share price forecasts

Forecast data provider AI Pickup’s MMM stock forecast was bullish for the upcoming years, as it expected the diversified manufacturing group’s share price to average $204.39 in 2022 — an upside of 34.25% from the close on 12 August.

According to the platform, the MMM share price could fall next year to average $194.93 in 2023 before stabilising around that mark to post a similar average of $194.68 in 2024. AI Pickup’s 3M stock forecast for 2025 had MMM averaging $220.08 throughout the year.

Algorithm-based forecasting website WalletInvestor’s 3M stock forecast for 2022 was bearish, predicting an average price of $149.691 by the end of the year. WalletInvestor predicted the share price to fall to $130.977 by the end of 2025.

When considering whether to invest in any company’s stock, you should always do your own research, considering the outlook and relevant market conditions. A number of factors dictate whether stock prices rise or fall, including the company’s fundamentals and broader macro-economic factors.

Remember that there are no guarantees and that markets are volatile. You should conduct your own analysis, taking in such things as the environment in which it trades and your risk tolerance, and never invest money that you cannot afford to lose.


Is 3M a good stock to buy?

Analysts are mixed on the market outlook for 3M stocks. Although the group reported better-than-expected earnings in Q2 and plans to spin off its healthcare arm in 2023, the impending lawsuits on its combat earplugs and potential rising litigation costs continue to weigh on investors’ sentiment.

However, whether it is a good buy or not will depend on your investing goals and portfolio composition. You should do your own research and never invest what you cannot afford to lose.

Will 3M stock go up or down?

Views are mixed on the 3M stock price trend. As of 15 August 2022, AI Pickup forecast the share price to rise in the coming years before falling slightly, while WalletInvestor expected 3M stock to fall between 2022 and 2027.

You should do your own research and never invest any money you cannot afford to lose.

Should I invest in 3M stock?

As of 15 August 2022, 3M (MMM) stock had lost approximately 14% of its value this year. Your decision to purchase MMM stock should be based on your risk tolerance, portfolio size and goals, and stock market experience.

You should always conduct your research to determine whether a stock is suitable for you. Remember that previous results do not guarantee future returns, and never invest any money that you cannot afford to lose.

Further reading


What You Need to Know

The week ahead update on major market events in your inbox every week. Subscribe
The difference between trading assets and CFDs
The main difference between CFD trading and trading assets, such as commodities and stocks, is that you don’t own the underlying asset when you trade on a CFD.
You can still benefit if the market moves in your favour, or make a loss if it moves against you. However, with traditional trading you enter a contract to exchange the legal ownership of the individual shares or the commodities for money, and you own this until you sell it again.
CFDs are leveraged products, which means that you only need to deposit a percentage of the full value of the CFD trade in order to open a position. But with traditional trading, you buy the assets for the full amount. In the UK, there is no stamp duty on CFD trading, but there is when you buy stocks, for example.
CFDs attract overnight costs to hold the trades (unless you use 1-1 leverage), which makes them more suited to short-term trading opportunities. Stocks and commodities are more normally bought and held for longer. You might also pay a broker commission or fees when buying and selling assets direct and you’d need somewhere to store them safely.
Capital Com is an execution-only service provider. The material provided on this website is for information purposes only and should not be understood as an investment advice. Any opinion that may be provided on this page does not constitute a recommendation by Capital Com or its agents. We do not make any representations or warranty on the accuracy or completeness of the information that is provided on this page. If you rely on the information on this page then you do so entirely on your own risk.

Still looking for a broker you can trust?

Join the 450.000+ traders worldwide that chose to trade with

1. Create & verify your account

2. Make your first deposit

3. You’re all set. Start trading